Ipsen: worldwide licensing agreement with Foreseen

(CercleFinance.com) - Ipsen announces the signature of a licensing agreement with Foreseen Biotechnology, for exclusive worldwide rights to develop, manufacture and market FS001, a potentially first-in-class drug.


Identified using Foreseen's proprietary proteomics platforms, this antibody-drug conjugate has demonstrated robust preclinical efficacy in multiple tumor types and a favorable preclinical safety profile, according to Ipsen.

Foreseen will receive up to $1.03bn in upfront and milestone payments. It may also receive tiered royalties on global sales.


Copyright (c) 2024 CercleFinance.com. All rights reserved.